Lupin is a USD 2.06 billion innovation led transnational pharmaceutical major producing and developing a wide range of branded and generic formulations as well as biotechnology products and APIs globally. The Company is a significant player in the Cardiovascular, Diabetology, Asthma, Pediatric, CNS, GI, Anti-Infective and NSAID space and holds global leadership positions in the Anti-TB and Cephalosporin segment. Lupin is the 6th largest and fastest growing top 5 generics player in the US (5.3% market share by prescriptions, IMS Health) and the 3rd largest Indian pharmaceutical company by sales. The Company is also the fastest growing top 10 generic pharmaceutical players in Japan and South Africa (IMS). For the financial year ended March 2014, Lupin's Consolidated turnover and Profit after Tax were Rs. 120,600 million (USD 2.06 billion) and Rs. 18,364 million (USD 393 million) respectively.

Show more
TypePublic
HQMumbai, IN
Founded1968
Size (employees)16,792 (est)
Websitelupin.com
Lupin was founded in 1968 and is headquartered in Mumbai, IN
Report incorrect company information

Viewing summary data as a guest

Sign up for free to see all data

Lupin Office Locations

Lupin has offices in Mumbai, Baltimore and Zug
Mumbai, IN (HQ)
Laxmi Towers BKC Road
Mumbai, IN
Highway House Jawaharlal Nehru Rd
Zug, CH
1 Landis + Gyr-Strasse
Show all (4)
Report incorrect company information

Lupin Online and Social Media Presence

Embed Graph
Report incorrect company information

Lupin News and Updates

Lupin receives Europe's positive opinion for antimyotonic agent 'NaMuscla'

The CHMP's positive opinion will now be reviewed by the European Commission (EC), which has the authority to approve medicines for the European Union (EU), the Mumbai-based firm added

Lupin Neurosciences Announces Positive CHMP Opinion for NaMuscla™ for the Treatment of Myotonia in Non-Dystrophic Myotonic Disorders

Lupin Neurosciences Announces Positive CHMP Opinion for NaMuscla™ for the Treatment of Myotonia in Non-Dystrophic Myotonic Disorders

Lupin gets 5 observations from USFDA for Pithampur plant

Drug maker Lupin said Friday the US Food and Drug Administration has issued five observations after inspecting its Pithampur based manufacturing unit, sending its shares down by close to 2 per cent. The inspection at Pithampur Unit-3 (Indore) was a GMP inspection for the facility and also a Pre-Appr…

Lupin gets 5 observations from USFDA for Pithampur plant; shares fall 2%

The inspection at the site was conducted between October 8 and October 18, 2018

Lupin Ltd spurts 1.62%, gains for third straight session

The stock is quoting at Rs 901.2, up 1.62% on the day as on 12:49 IST on the NSE. Lupin Ltd is down 15.48% in last one year as compared to a 3.31% gain in NIFTY and a 0.59% gain in the Nifty Pharma index.

Rakesh Jhunjhunwala Tweaks Positions In DHFL, SpiceJet And Lupin

Jhunjhunwala buys more DHFL, SpiceJet, sells Lupin.
Show more
Report incorrect company information

Lupin Company Life and Culture

Report incorrect company information